• Users Online: 221
  • Print this page
  • Email this page
Year : 2020  |  Volume : 3  |  Issue : 1  |  Page : 8-11

Implementation of molecular markers in glioma histology reporting: A survey

Department of Neurosurgery, Apollo Hospital; Founder-Director, Exsegen Research Private Limited, Hyderabad, Telangana, India

Correspondence Address:
Dr. Amitava Ray
Department of Neurosurgery, Apollo Hospital, Jubilee Hills, Hyderabad - 500 033, Telangana; Exsegen Research Private Limited, Jubilee Hills, Hyderabad - 500 033, Telangana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/IJNO.IJNO_8_20

Rights and Permissions

Purpose: The purpose of this study is to judge the extent of implementation of the Indian Society of Neuro-Oncology (ISNO) guidelines for the incorporation of molecular markers in glioma histopathological reporting. Materials and Methods: This study was conducted electronically. A form was created on Google Forms and the link was shared on E-mail and WhatsApp to members of the Neurological Society of India and ISNO. Results: One hundred doctors replied to the questionnaire, and the majority worked in large tertiary care hospitals in big cities. However, practitioners from smaller tier 2 and tier 3 cities also participated. Sixty-eight percent of those who responded were neurosurgeons and more than two-thirds of all respondents had a specific interest in neuro-oncology. More than 90% thought that molecular markers added value to histopathology alone, but a much smaller number (12%) had the infrastructure to test all the markers. Only 10% relied on histopathology exclusively, without performing any molecular tests. Lack of adequate infrastructure and the additional cost that was usually borne by the patient were the two largest roadblocks in its wider acceptance. There was also an overwhelming majority of clinicians who thought that the current pathology reports should change and indicate not only the tumor type but include active pathways and suggest the best options for treatment. Conclusion: In spite of the roadblocks, there has been a fair amount of success in clinicians successfully testing for molecular markers in gliomas. As testing becomes more specific and sensitive and treatment becomes targets to specific molecular pathways, analysis of molecular pathways will become integral to glioma histopathology.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded221    
    Comments [Add]    

Recommend this journal